Novo Nordisk Sued in US Over GLP-1 Drug Semaglutide and NAION Blindness Risk

The litigation focuses on NAION, a rare but serious vision condition, and its alleged link to semaglutide's diabetes formulation. For Novo Nordisk, the reputational and legal stakes extend beyond this drug to the broader GLP-1 class, where safety scrutiny is already intense. Patients and prescribers face the question of whether such signals warrant changes to risk disclosures. The key thing to watch is whether these claims remain isolated or prompt wider regulatory or labeling action.